CTI Clinical Trial and Consulting Supports Growing Business with Expanded Oracle Clinical Footprint

CTI Clinical Trial and Consulting Services (CTI) is upgrading and expanding its use of Oracle applications for clinical development to support the company’s continued growth in the U.S. and global markets.

CTI, a specialty drug and market development company based in Cincinnati, Ohio, has recently upgraded to the newest releases of Oracle® Clinical and Oracle Adverse Event Reporting System.

The company is also upgrading to Oracle Remote Data Capture 4.5.3, Oracle’s electronic data capture (EDC) solution, to leverage new functionality designed to meet the needs of trial sponsors and investigative site personnel, including the product’s zero-client footprint that enables improved global access.

The growing company, which serves more than 50 biotech and pharmaceutical organizations globally is expanding its Oracle footprint with the deployment of Oracle’s Siebel Clinical Trial Management System, moving from a system developed in house to a best-of-breed solution that provides greater scalability and flexibility in managing all aspects of clinical study planning, preparation, performance and reporting.

The company focuses on developing therapies targeting very ill patients. The clinical trial process for such drugs often requires more frequent, extensive and rapid reporting to a trial’s Data Safety Monitoring Board (DSMB), an independent body responsible for assessing a study and its risk.

With Oracle Clinical and Oracle Remote Data Capture, CTI can quickly deliver data to a DSMB or regulatory agencies, such as the U.S. Food and Drug Administration (FDA), without the need to key in information from paper case report forms (CRFs) – a process that is time consuming and presents opportunities for data entry error.

CTI conducts approximately 60 percent of its trials using EDC technology.

The 10-year old company invested in industry-leading Oracle Clinical applications at its inception to help credential it in the market.

“We invested in Oracle’s clinical applications suite from the very start of our organization because it is a leader that has the confidence of the biotech and pharmaceutical industry. Over the years, Oracle has been very flexible and eager to work with our emerging organization, playing an important supporting role in continued growth,” said Tim Schroeder, Chief Executive Officer, CTI Clinical Trial and Consulting Services.

“We view the launch of the Oracle Health Sciences Global Business Unit earlier this year as a very positive development, further strengthening Oracle’s commitment to and expertise in the industry. We are also eager to explore the value that Oracle’s movement toward expanded integration among its clinical applications can deliver to organizations like ours,” said Tim Schroeder, Chief Executive Officer, CTI Clinical Trial and Consulting Services.

“CTI, through its long-time commitment to and success with Oracle Clinical applications, demonstrates how emerging life sciences organizations can leverage Oracle applications to help drive growth and value within their organizations,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences Global Business Unit. “CTI is a compelling example of how Oracle applications can help life sciences organizations accelerate insights for better health, and we look forward to our continued relationship.”